Why Eli Lilly (LLY) rose 6.46%
Eli Lilly (LLY) rose 6.46% on October 30, 2026 — Raised FY guidance after strong Q3 beat.
What happened
Eli Lilly rose 6.4% after reporting Q3 revenue of $24.40B against $22.52B expected and adjusted EPS of $7.48 versus $5.59 expected.
Why it moved
A beat of this size on both revenue and EPS, paired with a guidance raise, forces analysts to lift full-year forecasts, which is why the stock re-rated higher.
Why it matters
Lilly is the clearest beneficiary of the Healthcare & Biotech theme's GLP-1 adoption story. Strong Mounjaro and Zepbound sales show that adoption is translating into revenue, not just expectations.
What would break the thesis
The risk is that the raised guidance gets walked back or that supply constraints cap future growth. Either would undo the upward earnings revisions that drove the rerating.
Sources
- ELI LILLY Q3 2026 EARNINGS - REV: $24.40B (EST $22.52B) - ADJ EPS: $7.48 (EST $5.59) - ZEPBOUND REV: $5.35B (EST $5.01B) - MOUNJARO REV: $10.7B (EST $9.95B) - FOUNDAYO REV: $184M (EST $231.2M) - SEES FY REV: $91.0B TO $92.0B (PREV $85.0B TO $87.0B) - SEES FY ADJ EPS: $35.00 TO… — MarketFeed
- Lilly’s obesity drug strength fuels record rally, Wall Street optimism — Investing.com
- ELI LILLY SHARES HIT RECORD HIGH AT THE OPEN ON OUTLOOK RAISE — MarketFeed